drugset
drugset / Trial / NCT01443377

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

NCT01443377 ↗

Phase 2 Completed 48 enrolled National Center for Tumor Diseases, Heidelberg
NaSingle-groupOpen-labelTreatment

Summary

This study aims to investigate the combination of panitumumab and a 5-FU-based RCTX in patients with locally advanced KRAS wild-type rectal cancer.

Timeline

Start
2011-07
Primary completion
2012-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Panitumumab Monoclonal antibody 6 mg/kg Intravenous

Indications

rectal cancer